Tandem Diabetes Care - TNDM Stock Forecast, Price & News

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Analyst Upgrades and Downgrades

TNDM has been the subject of a number of analyst reports. Citigroup cut their price target on Tandem Diabetes Care from $107.00 to $98.00 in a report on Thursday, August 4th. Cowen decreased their target price on Tandem Diabetes Care from $141.00 to $107.00 in a research report on Thursday, August 4th. TheStreet downgraded Tandem Diabetes Care from a "c-" rating to a "d+" rating in a research report on Monday, June 13th. Robert W. Baird cut their price target on Tandem Diabetes Care to $76.00 in a research note on Tuesday, August 9th. Finally, Raymond James cut their price objective on Tandem Diabetes Care from $125.00 to $90.00 and set an "outperform" rating on the stock in a research note on Thursday, August 4th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $103.36.

Tandem Diabetes Care Stock Performance

TNDM opened at $53.89 on Monday. The company has a fifty day moving average price of $59.82 and a two-hundred day moving average price of $87.27. The company has a quick ratio of 5.36, a current ratio of 6.00 and a debt-to-equity ratio of 0.63. Tandem Diabetes Care has a 52 week low of $52.08 and a 52 week high of $155.86.

Insiders Place Their Bets

In other Tandem Diabetes Care news, COO David B. Berger sold 10,097 shares of Tandem Diabetes Care stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $65.02, for a total transaction of $656,506.94. Following the completion of the sale, the chief operating officer now owns 2,457 shares of the company's stock, valued at approximately $159,754.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Tandem Diabetes Care news, COO David B. Berger sold 10,097 shares of Tandem Diabetes Care stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $65.02, for a total transaction of $656,506.94. Following the completion of the sale, the chief operating officer now owns 2,457 shares of the company's stock, valued at approximately $159,754.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kim D. Blickenstaff sold 10,762 shares of the business's stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $92.91, for a total transaction of $999,897.42. Following the completion of the transaction, the director now directly owns 205,190 shares of the company's stock, valued at approximately $19,064,202.90. The disclosure for this sale can be found here. Company insiders own 2.20% of the company's stock.